The pneumocandins, isolated as fermentation products produced by Zalerion arboricola ATCC20868 1} and related semisynthetic derivatives,2) were evaluated in murine models for acute Pneumocystis carinii pneumonia3) and disseminated candidiasis infection40 following the discovery that pneumocandin Ao (L-671,329 ) was active against both pathogens.3'5) Pneumocandins were also evaluated in vitro against a panel of clinically relevant pathogenic fungi and in a Candida albicans membrane l,3-/?-D-glucan synthesis assay, since the proposed mechanism of action of these compounds is alteration of the cell wall via the inhibition of l ,3-/?-D-glucan synthesis.6)
The pneumocandins are closely related to the echinocandins,7) another family of lipopeptides with antifungal activity and are, therefore, compared here to two members of this class, tetrahydroechinocandin B and cilofungin. 8) Someechinocandins characteristically hemolyze humanand mouseerythrocytes in vitro at therapeutically useful concentrations,9* while pneumocandin Ao (L-671,329) exhibits low hemolytic potential.5) To determine the hemolytic potential of this class of compounds, all of the pneumocandins were evaluated in a red hemolysis assay.
The data generated in this study demonstrate that the pneumocandins are potent antifungal agents. This collection of closely related structures allows for the development of some initial structure-activity relationships and demonstrates that there is divergence in activity against P. carinii and C. albicans.
Materials and Methods

Compounds
All of the naturally occuring pneumocandins were isolated and purified by the Merck Natural Products Isolation group. The semisynthetic lipopeptides used for these studies were synthesized by the Merck Synthetic Chemical Research group from natural products produced in the department of Fermentation Microbiology and isolated by the Natural Products Isolation group. Trimethoprim and sulfamethoxazole were obtained from Phoenix Pharmaceuticals (St. Louis, MO).Pentamidine isethionate was obtained from Sigma (St. Louis, MO). Test compounds were solubilized in 10%DMSO.Amphotericin B (AMB) was prepared according to the manufacturer's instructions for Fungizone (E. R. Squibb).
Glucan Synthase Inhibition Assay
Buffer A: 10% glycerol (1.2 m) in phosphate buffered saline (PBS) containing phenylmethylsolfonyl fluoride (PMSF) (0.5 him) and dithiothreitol (DTT) (1 mM). Buffer B: Same as buffer A, but without PMSF and DTT. Buffer C: Dulbecco's PBS, pH 7.0 (Gibco, Grand Island, NY) containing EDTA (5 mM) and DTT (50 him). oc-Amylase stock solution: The enzyme was obtained from Sigma Chemical Co., St. Louis, MO,supplied as a suspension in ammoniumsulfate. This suspension (10^1, 0.24mg protein, equivalent to 264units) was diluted with 115/xl buffer B. UDP-[6, 3H]-glucose was obtained from Amersham Radiochemicals, Arlington Heights, IL, supplied at 250//Ci/250[A (14.7 Ci/mmol); 5 /xl of a 1 : 5 dilution (500,000 dpm) is equivalent to 77pmol. GTP-y-S was obtained from Sigma.
Candida albicans (MY 1208) cells were grown to early log phase (6~8 hours) in 500ml of Sabouraud Dextrose broth (Difco) in a 2-liter baffled shake flask at 28°C at 150rpm. The membrane-associated synthase system was prepared from protoplasts essentially by the method of Taft et al.l0 ) The assay of 3H-glucan was conducted as a modification of the method previously described by Cabib and Kang for Saccharomycescerevisiae.1 1] The total volume in wells of a microtiter plate designed for automated collection of the products of synthesis was 80//I. The incubation system contained 6.6% DMSO, 125mM Tris-HCl (pH 7.5), 0.25mM DTT, 0.15him PMSF, 0.4m glycerol, 0.75mM EDTA, 0.25% BSA, 40mM GTP-y-S, 2.5 mMlaminaribiose, 30 units/system of a-amylase, synthase (500 fig protein/ml assay system) contained in 15 /xl and 25 /mi UDP-glucose, the required concentration added in 10/A including UDP-
To determine the inhibitiory effect of analogs, samples were added at 1.5mMand serially diluted to a level of 0.04jum. Compounds for evaluation were contained in 4^1 of 50% DMSO. During the assay, microtiter plates were covered with Parafilm and incubated for 60 minutes at 24°C with agitation on a Minimix stand (Fisher Scientific). The reaction was terminated by the addition ofTCA(10%, 100 /xl/well) and the resulting insoluble materials were collected on a glass filter mat in a Wallac (LKB) cell harvester, followed by automated wash cycles (water and 95% ethanol). The incorporated radiolabel per well was determined in a model 1205 Betaplate liquid scintillation counter (LKB, Wallac). The l,3-j5-D-glucan synthesis inhibitory concentration (IC50) was defined as the concentration at which a compound inhibited 50% of the production of acid precipitable product.
Broth Microdilution Assay for MinimumInhibitory and Fungicidal Determinations
Compoundswere evaluated against a selected panel of clinically relevant fungi for the determination of antifungal spectrum and potency. Broth microdilution methodology was employed to determine minimum fungicidal concentrations (MFC) as described previously.12) MFCvalues were determined by removing aliquots from each well and plating them on compound-free agar mediumand denned as the lowest concentration of compoundsshowing less than 4 colonies.
Red Blood Cells (RBC) Lysis Assay A 4%-suspension of freshly drawn whole heparinized human or CD-I mouse blood was prepared by adding 2.0ml of blood to 50ml sterile 5% glucose. Compounds were solubilized in 10% DMSOat a concentration of 4.0mg/ml and further diluted to a concentration of 0.5^g/ml by the addition of sterile 5%glucose. Test compounds were dispensed into wells of microtiter plates and serially two-fold diluted in 5% glucose and then 38 fil of RBCsuspension was added to each well to yield final test concentrations of 400 to 0.20 /ig/ml. Plates were gently and incubated at room temperature and results were determined after 2 hours of incubation. Hemolysis of erythrocytes cells was indicated by complete or partial clearing (lysis). Minimumlytic concentration (MLC) is defined as the lowest concentration of a test compound which produces complete or partial lysis of erythrocytes. DEC. 1992 The Target Organ Kidney Assay (TOKA)-Evaluation of In Vivo Efficacy Against Candida albicans The Target Organ Kidney Assay (TOKA)used for evaluation of antifungal efficacy against C. albicans has been described in detail previously.4) Briefly, C. albicans MY1055 was administered iv in the tail veins DBA/2mice, at an inoculum of7. The dexamethasone-immunosuppressed rat model used in these studies has been described in detail elsewhere.3) Toevaluate the efficacy of the compounds in this model, rats immunosuppressed for six weeks were treated intraperitoneally or subcutaneously, b.i.d. for four days. All compoundswere solubilized in 10%DMSO and injected in a 0.5 ml volume. Compoundswere tested at the appropriate levels to establish an ED90. Each test group contained 6 rats. On the morning following the last dose, rats were sacrificed and their lungs were removed and processed according to the procedure outlined previously.3)
Results and Discussion
The in vivo ED90values for the pneumocandins ranged from 0.15mg/kg to >2.5mg/kg against P. carinii and from 0.35mg/kg to >6.00mg/kg for C. albicans (Table 1) . Pneumocandin Bo was the best dual purpose compound in the series for the treatment of P. carinii and C. albicans. It also had the broadest anticandida spectrum and potency in vitro (Table 2 ). These were obvious differences in the structure-activity relationships (SAR) for the pneumocandin compounds against these two pathogens in vivo. The anticandida activity was depressed in compounds reduced at both R^and R2 such as pneumocandin A2, pneumocandin A4 and pneumocandin B2, while antipneumocystis activity was generally less sensitive to these changes. The anticandida activity was also depressed in pneumocandinCo whenthere was a 4-hydroxyproline rather than a 3-hyroxyproline (pneumocandin Bo). In contrast compound pneumocandin Co retained antipneumocystis activity which was comparable to pneumocandinBo. The compoundswhich appeared to have reduced antipneumocystis activity were pneumocandin A4, semisynthetic bis-reduced compounds L-691,936 and L-692,289 and mono-reduced L-706,577 indicating that the R3 hydroxyl is important for potent antipneumocystis activity. In contrast reduction at R3 had less influence on the anticandida activity.
The lack of an in vitro assay for P. carinii makes it difficult to determine if the SARdifferences seen relative to anticandida activity with these compoundswere due to intrinsic potency or pharmacokinetic differences between the mouseand the rat. Since P. carinii resides exclusively in the lungs and C. albicans efficacy determinations were conducted on kidney tissue, differences in tissue distribution of the compounds could account for divergent SAR's. Tissue distribution studies with radiolabeled pneumocandin Bo have indicated that there was little difference in distribution of this compoundin lungs relative to kidneys (R. Hajdu, unpublished data, not shown). However, pneumocandin Bo is one of the few compoundswith good efficacy against both pathogens and tissue distribution data is not available for other compounds which are selective for C. albicans or P. carinii. Evaluation of the whole body distribution of other pneumocandins would aid in determining if the difference is due to the concentration of compound in specific tissues. The divergence of SAR's is further exemplified by comparing the antipneumocystis activity of tetrahydroechinocandin B and cilofungin ( PCP is the P. carinii pneumonia in vivo results, TOKAis the target organ kidney assay for C. albicans in vivo, MLCis the minimum lytic concentration with human or mouse erythrocytes and l,3-/?-D-glucan is the IC50 for glucan synthesis inhibition in vitro. DEC. 1992 Theparticular strain of each species of Candidais listed abovethe species name.
active than cilofungin against C. albicans in vivo there is a substantial difference in the activity of these two compounds against P. carinii. Furthermore the potent antipneumocystis activity of tetrahydroechinocandin B implies that the cilofungin side chain (/?-(«-octyloxy)benzoyl) is responsible for the loss of this activity.
The l,3-/?-D-glucan IC50's did not correlate well with the in vitro anticandida activity and may be attributable to permeability differences of viable yeast cells. A l,3-/?-D-glucan synthesis assay, in which inhibition by the lipopeptides can be measured, has not been established for P. carinii.
Most of the pneumocandins were not hemolytic with the exception of pneumocandin A2, L-706,577 and pneumocandin Co which were mildly hemolytic (200~400 /ig/ml) relative to an MLCof 25 //g/ml for tetrahydroechinocandin B. Cilofungin was not hemolytic ( >400 //g/ml) as previously reported and was originally selected from a series of semisynthetic echinocandins for further development in part due to the lack of hemolytic activity.9)
In summary, the pneumocandins are potentially useful for both Candida and Pneumocystis infections, both of which are prevalent in the immunocompromised patient. The reduced hemolytic potential of pneumocandin Ao (L-671,329) seems to be consistent throughout this group of compounds suggesting that these compoundsmaybe safer than the other naturally occuring echinocandins. Although inhibition of l,3-/?-D-glucan synthesis is the proposed mechanism of action of these compounds this has not been demonstrated in the case of P. carinii other than reports of the assumed presence of l,3-/?-D-glucan polymer in the wall of the cysts.13'14) The divergence in SARand differences in potency against C. albicans and P. carinii suggests that there may be a difference in the target between in these two pathogens.
